 |
|
Aptiganel Hydrochloride in Acute Ischemic Stroke
A Randomized Controlled Trial
Gregory W. Albers, MD;
Larry B. Goldstein, MD;
David Hall, PhD;
Lynna M. Lesko, MD, PhD;
for the Aptiganel Acute Stroke Investigators
JAMA. 2001;286:2673-2682.
Context Tissue plasminogen activator is the only thrombolytic agent approved in the United States for treatment of acute ischemic stroke, and has limitations. Aptiganel hydrochloride is a novel and selective ligand for the ion-channel site of the N-methyl-D-aspartate receptor-channel complex and a promising neuroprotective agent in animal models of focal brain ischemia.
Objective To determine whether aptiganel improves the clinical outcome for acute ischemic stroke patients.
Design Nested phase 2/phase 3 randomized controlled trial conducted between July 1996 and September 1997.
Setting One hundred fifty-six medical centers in the United States, Canada, Australia, South Africa, England, and Scotland.
Participants A total of 628 patients with hemispheric ischemic stroke (50.3% male; mean age, 71.5 years).
Interventions Patients were randomly assigned within 6 hours of stroke to receive 1 of 3 treatment regimens: high-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n = 214); low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n = 200); or placebo (n = 214).
Main Outcome Measures The primary efficacy end point was the Modified Rankin Scale score at 90 days after stroke onset. Secondary end points included mortality and change in National Institutes of Health (NIH) Stroke Scale score at 7 days after stroke.
Results The trial was suspended by the sponsor and the independent data and safety monitoring board because of both a lack of efficacy and a potential imbalance in mortality. There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P = .31). At 7 days, placebo-treated patients exhibited slightly greater neurological improvement on the NIH Stroke Scale than high-dose aptiganel patients (mean improvement for placebo group, -0.8 points vs for high-dose aptiganel, 0.9 points; P = .04). The mortality rate at 120 days in patients treated with high-dose aptiganel was higher than that in patients who received placebo (26.3% vs 19.2%; P = .06). Mortality in the low-dose aptiganel group was 22.5% (P = .39 vs placebo).
Conclusions Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful. The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.
Author Affiliations: Stanford Stroke Center, Stanford University Medical Center, Palo Alto, Calif (Dr Albers); Departments of Medicine and Neurology, Duke Center for Cerebrovascular Disease, Duke University Medical Center, and VA Medical Center, Durham, NC (Dr Goldstein); and Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Conn (Drs Hall and Lesko).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Patient Safety in Trials of Therapy for Acute Ischemic Stroke
Larry B. Goldstein, Gregory W. Albers, Kyra J. Becker, and David L. Tirschwell
JAMA. 2002;287(8):987.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Ensuring Patient Safety in Clinical Trials for Treatment of Acute Stroke
Kyra J. Becker and David L. Tirschwell
JAMA. 2001;286(21):2718-2719.
EXTRACT
| FULL TEXT
December 5, 2001
JAMA. 2001;286(21):2745-2746.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview
Ginsberg
Stroke 2009;40:S111-S114.
ABSTRACT
| FULL TEXT
Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier
Hermann
Therapeutic Advances in Neurological Disorders 2008;1:167-179.
ABSTRACT
Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand
Soriano et al.
J. Neurosci. 2008;28:10696-10710.
ABSTRACT
| FULL TEXT
The Dichotomy of NMDA Receptor Signaling
Papadia and Hardingham
Neuroscientist 2007;13:572-579.
ABSTRACT
Compartmentalized NMDA receptor signalling to survival and death
Soriano and Hardingham
J. Physiol. 2007;584:381-387.
ABSTRACT
| FULL TEXT
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Adams et al.
Circulation 2007;115:e478-e534.
ABSTRACT
| FULL TEXT
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Adams et al.
Stroke 2007;38:1655-1711.
ABSTRACT
| FULL TEXT
Recruiting Subjects for Acute Stroke Trials: A Meta-Analysis
Elkins et al.
Stroke 2006;37:123-128.
ABSTRACT
| FULL TEXT
Revising a Dogma: Ketamine for Patients with Neurological Injury?
Himmelseher and Durieux
Anesth. Analg. 2005;101:524-534.
ABSTRACT
| FULL TEXT
Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome
Weaver et al.
Stroke 2004;35:1216-1224.
ABSTRACT
| FULL TEXT
Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association
Adams et al.
Circulation 2003;108:1278-1290.
FULL TEXT
Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association
Adams et al.
Stroke 2003;34:2310-2322.
FULL TEXT
UK-279,276, a Neutrophil Inhibitory Glycoprotein, in Acute Stroke: Tolerability and Pharmacokinetics
Lees et al.
Stroke 2003;34:1704-1709.
ABSTRACT
| FULL TEXT
Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-D-Aspartate Antagonist
Gill et al.
J. Pharmacol. Exp. Ther. 2002;302:940-948.
ABSTRACT
| FULL TEXT
Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions
Gladstone et al.
Stroke 2002;33:2123-2136.
ABSTRACT
| FULL TEXT
Patient Safety in Trials of Therapy for Acute Ischemic Stroke
Goldstein et al.
JAMA 2002;287:987-987.
FULL TEXT
Ensuring Patient Safety in Clinical Trials for Treatment of Acute Stroke
Becker and Tirschwell
JAMA 2001;286:2718-2719.
FULL TEXT
|
